Nonalcoholic fatty liver disease associated with metabolic syndrome: Influence of liver fibrosis stages on characteristics of very low-density lipoproteins

Autores
Lucero, Diego Martín; Miksztowicz, Verónica Julieta; Gualano, Gisela; Longo, Cristina; Landeira, Graciela; Álvarez, Estela; Zago, Valeria; Brites, Fernando Daniel; Berg, Gabriela Alicia; Fassio, Eduardo; Schreier, Laura Ester
Año de publicación
2017
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Background We evaluated possible changes in VLDLcharacteristics, and metabolic related factors, in MetS-associated NAFLD and accompanying liver fibrosis. Methods We studied 36 MetS patients with biopsy-proven NAFLD (MetS + NAFLD) and 24 MetS without ultrasound NAFLD evidence. Further, MetS + NAFLD was sub-divided according to fibrosis stage into, non-to-moderate (F0–F2, n = 27) and severe (F3–F4, n = 9) fibrosis. We measured: lipid profile, VLDL composition and size (size exclusion-HPLC), CETP and lipoprotein lipase (LPL) activities and adiponectin. Additionally, in MetS + NAFLD type IV collagen 7S domain was measured. Results MetS + NAFLD showed increased VLDL-mass, VLDL particle number, VLDL-triglyceride% and large VLDL-% (p < 0.04). CETP activity tended to increase in MetS + NAFLD (p = 0.058), while LPL activity was unchanged. Moreover, in MetS + NAFLD, adiponectin was decreased (p < 0.001), and negatively correlated with VLDL-mass and VLDL particle number (p < 0.05), independently of insulin-resistance. Within MetS + NAFLD group, despite greater insulin-resistance, patients with severe fibrosis showed lower plasma triglycerides, VLDL-mass, VLDL-triglyceride%, large VLDL-% and CETP activity (p < 0.05), while type IV collagen was increased (p = 0.009) and inversely correlated with large VLDL-% (p = 0.045). Conclusions In MetS, NAFLD is associated with larger and triglyceride over-enriched circulating VLDLs, of greater atherogenicity. However, when NAFLD progresses to severe fibrosis, circulating VLDL features apparently improved, probably due to early alterations in hepatic synthetic function.
Fil: Lucero, Diego Martín. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; Argentina
Fil: Miksztowicz, Verónica Julieta. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; Argentina
Fil: Gualano, Gisela. Hospital Nacional “Profesor Alejandro Posadas”; Argentina
Fil: Longo, Cristina. Hospital Nacional “Profesor Alejandro Posadas”; Argentina
Fil: Landeira, Graciela. Hospital Nacional “Profesor Alejandro Posadas”; Argentina
Fil: Álvarez, Estela. Hospital Nacional “Profesor Alejandro Posadas”; Argentina
Fil: Zago, Valeria. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; Argentina
Fil: Brites, Fernando Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; Argentina
Fil: Berg, Gabriela Alicia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; Argentina
Fil: Fassio, Eduardo. Hospital Nacional “Profesor Alejandro Posadas”; Argentina
Fil: Schreier, Laura Ester. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; Argentina
Materia
Liver Fibrosis
Metabolic Syndrome
Nonalcoholic Fatty Liver Disease
Very Low-Density Lipoproteins
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/48624
Acceder
id CONICETDig_e65d33b2eb4968013bc5aa4defc7dde8
oai_identifier_str oai:ri.conicet.gov.ar:11336/48624
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Nonalcoholic fatty liver disease associated with metabolic syndrome: Influence of liver fibrosis stages on characteristics of very low-density lipoproteinsLucero, Diego MartínMiksztowicz, Verónica JulietaGualano, GiselaLongo, CristinaLandeira, GracielaÁlvarez, EstelaZago, ValeriaBrites, Fernando DanielBerg, Gabriela AliciaFassio, EduardoSchreier, Laura EsterLiver FibrosisMetabolic SyndromeNonalcoholic Fatty Liver DiseaseVery Low-Density Lipoproteinshttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Background We evaluated possible changes in VLDLcharacteristics, and metabolic related factors, in MetS-associated NAFLD and accompanying liver fibrosis. Methods We studied 36 MetS patients with biopsy-proven NAFLD (MetS + NAFLD) and 24 MetS without ultrasound NAFLD evidence. Further, MetS + NAFLD was sub-divided according to fibrosis stage into, non-to-moderate (F0–F2, n = 27) and severe (F3–F4, n = 9) fibrosis. We measured: lipid profile, VLDL composition and size (size exclusion-HPLC), CETP and lipoprotein lipase (LPL) activities and adiponectin. Additionally, in MetS + NAFLD type IV collagen 7S domain was measured. Results MetS + NAFLD showed increased VLDL-mass, VLDL particle number, VLDL-triglyceride% and large VLDL-% (p < 0.04). CETP activity tended to increase in MetS + NAFLD (p = 0.058), while LPL activity was unchanged. Moreover, in MetS + NAFLD, adiponectin was decreased (p < 0.001), and negatively correlated with VLDL-mass and VLDL particle number (p < 0.05), independently of insulin-resistance. Within MetS + NAFLD group, despite greater insulin-resistance, patients with severe fibrosis showed lower plasma triglycerides, VLDL-mass, VLDL-triglyceride%, large VLDL-% and CETP activity (p < 0.05), while type IV collagen was increased (p = 0.009) and inversely correlated with large VLDL-% (p = 0.045). Conclusions In MetS, NAFLD is associated with larger and triglyceride over-enriched circulating VLDLs, of greater atherogenicity. However, when NAFLD progresses to severe fibrosis, circulating VLDL features apparently improved, probably due to early alterations in hepatic synthetic function.Fil: Lucero, Diego Martín. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; ArgentinaFil: Miksztowicz, Verónica Julieta. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; ArgentinaFil: Gualano, Gisela. Hospital Nacional “Profesor Alejandro Posadas”; ArgentinaFil: Longo, Cristina. Hospital Nacional “Profesor Alejandro Posadas”; ArgentinaFil: Landeira, Graciela. Hospital Nacional “Profesor Alejandro Posadas”; ArgentinaFil: Álvarez, Estela. Hospital Nacional “Profesor Alejandro Posadas”; ArgentinaFil: Zago, Valeria. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; ArgentinaFil: Brites, Fernando Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; ArgentinaFil: Berg, Gabriela Alicia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; ArgentinaFil: Fassio, Eduardo. Hospital Nacional “Profesor Alejandro Posadas”; ArgentinaFil: Schreier, Laura Ester. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; ArgentinaElsevier Science2017-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/48624Lucero, Diego Martín; Miksztowicz, Verónica Julieta; Gualano, Gisela; Longo, Cristina; Landeira, Graciela; et al.; Nonalcoholic fatty liver disease associated with metabolic syndrome: Influence of liver fibrosis stages on characteristics of very low-density lipoproteins; Elsevier Science; Clinica Chimica Acta; 473; 10-2017; 1-80009-8981CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1016/j.cca.2017.08.006info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0009898117302991info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T14:41:05Zoai:ri.conicet.gov.ar:11336/48624instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 14:41:05.922CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Nonalcoholic fatty liver disease associated with metabolic syndrome: Influence of liver fibrosis stages on characteristics of very low-density lipoproteins
title Nonalcoholic fatty liver disease associated with metabolic syndrome: Influence of liver fibrosis stages on characteristics of very low-density lipoproteins
spellingShingle Nonalcoholic fatty liver disease associated with metabolic syndrome: Influence of liver fibrosis stages on characteristics of very low-density lipoproteins
Lucero, Diego Martín
Liver Fibrosis
Metabolic Syndrome
Nonalcoholic Fatty Liver Disease
Very Low-Density Lipoproteins
title_short Nonalcoholic fatty liver disease associated with metabolic syndrome: Influence of liver fibrosis stages on characteristics of very low-density lipoproteins
title_full Nonalcoholic fatty liver disease associated with metabolic syndrome: Influence of liver fibrosis stages on characteristics of very low-density lipoproteins
title_fullStr Nonalcoholic fatty liver disease associated with metabolic syndrome: Influence of liver fibrosis stages on characteristics of very low-density lipoproteins
title_full_unstemmed Nonalcoholic fatty liver disease associated with metabolic syndrome: Influence of liver fibrosis stages on characteristics of very low-density lipoproteins
title_sort Nonalcoholic fatty liver disease associated with metabolic syndrome: Influence of liver fibrosis stages on characteristics of very low-density lipoproteins
dc.creator.none.fl_str_mv Lucero, Diego Martín
Miksztowicz, Verónica Julieta
Gualano, Gisela
Longo, Cristina
Landeira, Graciela
Álvarez, Estela
Zago, Valeria
Brites, Fernando Daniel
Berg, Gabriela Alicia
Fassio, Eduardo
Schreier, Laura Ester
author Lucero, Diego Martín
author_facet Lucero, Diego Martín
Miksztowicz, Verónica Julieta
Gualano, Gisela
Longo, Cristina
Landeira, Graciela
Álvarez, Estela
Zago, Valeria
Brites, Fernando Daniel
Berg, Gabriela Alicia
Fassio, Eduardo
Schreier, Laura Ester
author_role author
author2 Miksztowicz, Verónica Julieta
Gualano, Gisela
Longo, Cristina
Landeira, Graciela
Álvarez, Estela
Zago, Valeria
Brites, Fernando Daniel
Berg, Gabriela Alicia
Fassio, Eduardo
Schreier, Laura Ester
author2_role author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Liver Fibrosis
Metabolic Syndrome
Nonalcoholic Fatty Liver Disease
Very Low-Density Lipoproteins
topic Liver Fibrosis
Metabolic Syndrome
Nonalcoholic Fatty Liver Disease
Very Low-Density Lipoproteins
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Background We evaluated possible changes in VLDLcharacteristics, and metabolic related factors, in MetS-associated NAFLD and accompanying liver fibrosis. Methods We studied 36 MetS patients with biopsy-proven NAFLD (MetS + NAFLD) and 24 MetS without ultrasound NAFLD evidence. Further, MetS + NAFLD was sub-divided according to fibrosis stage into, non-to-moderate (F0–F2, n = 27) and severe (F3–F4, n = 9) fibrosis. We measured: lipid profile, VLDL composition and size (size exclusion-HPLC), CETP and lipoprotein lipase (LPL) activities and adiponectin. Additionally, in MetS + NAFLD type IV collagen 7S domain was measured. Results MetS + NAFLD showed increased VLDL-mass, VLDL particle number, VLDL-triglyceride% and large VLDL-% (p < 0.04). CETP activity tended to increase in MetS + NAFLD (p = 0.058), while LPL activity was unchanged. Moreover, in MetS + NAFLD, adiponectin was decreased (p < 0.001), and negatively correlated with VLDL-mass and VLDL particle number (p < 0.05), independently of insulin-resistance. Within MetS + NAFLD group, despite greater insulin-resistance, patients with severe fibrosis showed lower plasma triglycerides, VLDL-mass, VLDL-triglyceride%, large VLDL-% and CETP activity (p < 0.05), while type IV collagen was increased (p = 0.009) and inversely correlated with large VLDL-% (p = 0.045). Conclusions In MetS, NAFLD is associated with larger and triglyceride over-enriched circulating VLDLs, of greater atherogenicity. However, when NAFLD progresses to severe fibrosis, circulating VLDL features apparently improved, probably due to early alterations in hepatic synthetic function.
Fil: Lucero, Diego Martín. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; Argentina
Fil: Miksztowicz, Verónica Julieta. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; Argentina
Fil: Gualano, Gisela. Hospital Nacional “Profesor Alejandro Posadas”; Argentina
Fil: Longo, Cristina. Hospital Nacional “Profesor Alejandro Posadas”; Argentina
Fil: Landeira, Graciela. Hospital Nacional “Profesor Alejandro Posadas”; Argentina
Fil: Álvarez, Estela. Hospital Nacional “Profesor Alejandro Posadas”; Argentina
Fil: Zago, Valeria. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; Argentina
Fil: Brites, Fernando Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; Argentina
Fil: Berg, Gabriela Alicia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; Argentina
Fil: Fassio, Eduardo. Hospital Nacional “Profesor Alejandro Posadas”; Argentina
Fil: Schreier, Laura Ester. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Universidad de Buenos Aires. Instituto de Fisiopatología y Bioquímica Clínica; Argentina
description Background We evaluated possible changes in VLDLcharacteristics, and metabolic related factors, in MetS-associated NAFLD and accompanying liver fibrosis. Methods We studied 36 MetS patients with biopsy-proven NAFLD (MetS + NAFLD) and 24 MetS without ultrasound NAFLD evidence. Further, MetS + NAFLD was sub-divided according to fibrosis stage into, non-to-moderate (F0–F2, n = 27) and severe (F3–F4, n = 9) fibrosis. We measured: lipid profile, VLDL composition and size (size exclusion-HPLC), CETP and lipoprotein lipase (LPL) activities and adiponectin. Additionally, in MetS + NAFLD type IV collagen 7S domain was measured. Results MetS + NAFLD showed increased VLDL-mass, VLDL particle number, VLDL-triglyceride% and large VLDL-% (p < 0.04). CETP activity tended to increase in MetS + NAFLD (p = 0.058), while LPL activity was unchanged. Moreover, in MetS + NAFLD, adiponectin was decreased (p < 0.001), and negatively correlated with VLDL-mass and VLDL particle number (p < 0.05), independently of insulin-resistance. Within MetS + NAFLD group, despite greater insulin-resistance, patients with severe fibrosis showed lower plasma triglycerides, VLDL-mass, VLDL-triglyceride%, large VLDL-% and CETP activity (p < 0.05), while type IV collagen was increased (p = 0.009) and inversely correlated with large VLDL-% (p = 0.045). Conclusions In MetS, NAFLD is associated with larger and triglyceride over-enriched circulating VLDLs, of greater atherogenicity. However, when NAFLD progresses to severe fibrosis, circulating VLDL features apparently improved, probably due to early alterations in hepatic synthetic function.
publishDate 2017
dc.date.none.fl_str_mv 2017-10
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/48624
Lucero, Diego Martín; Miksztowicz, Verónica Julieta; Gualano, Gisela; Longo, Cristina; Landeira, Graciela; et al.; Nonalcoholic fatty liver disease associated with metabolic syndrome: Influence of liver fibrosis stages on characteristics of very low-density lipoproteins; Elsevier Science; Clinica Chimica Acta; 473; 10-2017; 1-8
0009-8981
CONICET Digital
CONICET
url http://hdl.handle.net/11336/48624
identifier_str_mv Lucero, Diego Martín; Miksztowicz, Verónica Julieta; Gualano, Gisela; Longo, Cristina; Landeira, Graciela; et al.; Nonalcoholic fatty liver disease associated with metabolic syndrome: Influence of liver fibrosis stages on characteristics of very low-density lipoproteins; Elsevier Science; Clinica Chimica Acta; 473; 10-2017; 1-8
0009-8981
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1016/j.cca.2017.08.006
info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0009898117302991
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier Science
publisher.none.fl_str_mv Elsevier Science
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846082905649971200
score 13.22299

Publicaciones similares